Related references
Note: Only part of the references are listed.COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?
Cheryl L. Maier et al.
LANCET (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)
Neil Mehta et al.
JAMA CARDIOLOGY (2020)
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19
Giuseppe Mancia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Angiotensin II, tissue factor and the thrombotic paradox of hypertension
Alessandro Celi et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2010)
Regulation of ACE2 in cardiac myocytes and fibroblasts
Patricia E. Gallagher et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats
I. Hamming et al.
EXPERIMENTAL PHYSIOLOGY (2008)
Share Paper
